MS Stock Recent News

Wealth management and asset flows keep growing steadily, despite market volatility. Cost discipline and a strong capital position boost earnings and flexibility. The market still undervalues Morgan Stanley's new business mix.

Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302 Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302

NEW YORK--(BUSINESS WIRE)--Morgan Stanley (NYSE: MS) today announced that Lynn Good has been elected to the Company's Board of Directors, effective July 18, 2025. Ms. Good, 66, is the former Chair, CEO and President of Duke Energy. Her appointment will bring Morgan Stanley's Board of Directors to 15 members. She will serve on the Board's Audit Committee. Ted Pick, Chairman and CEO of Morgan Stanley, said, “We are very happy to welcome Lynn Good to our Board. As the former Chair and CEO of Duke.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Morgan Stanley (MS) have what it takes?

Morgan Stanley (MS) closed the most recent trading day at $129.49, moving 1.84% from the previous trading session.

Zacks.com users have recently been watching Morgan Stanley (MS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

In a significant financial move, Morgan Stanley is marketing a $5 billion debt package for Elon Musk's artificial intelligence startup, xAI. This development comes at a time of heightened public tension between Musk, the world's richest individual, and U.S. President Donald Trump, adding a layer of complexity to the fundraising efforts.

Squarepoint Ops LLC lowered its position in shares of 8×8, Inc. (NASDAQ:EGHT – Free Report) by 80.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,454 shares of the company’s stock after selling 99,056 shares during the period. Squarepoint Ops LLC’s holdings in 8X8 were worth $63,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other hedge funds and other institutional investors have also made changes to their positions in the company. Two Sigma Advisers LP boosted its position in shares of 8X8 by 39.2% during the 4th quarter. Two Sigma Advisers LP now owns 1,218,758 shares of the company’s stock worth $3,254,000 after purchasing an additional 343,400 shares during the period. Two Sigma Investments LP boosted its position in shares of 8X8 by 49.2% during the 4th quarter. Two Sigma Investments LP now owns 1,014,048 shares of the company’

Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,461 shares of the company’s stock, valued at approximately $59,000. A number of other large investors also recently bought and sold shares of the stock. SG Americas Securities LLC raised its stake in TScan Therapeutics by 31.2% during the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after purchasing an additional 4,852 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after acquiring an additional 5,694 shares in the last quarter. Wellington Management Group LLP lift

Squarepoint Ops LLC purchased a new position in shares of U.S. Gold Corp. (NASDAQ:USAU – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,292 shares of the technology company’s stock, valued at approximately $69,000. Squarepoint Ops LLC owned 0.09% of U.S. Gold at the end of the most recent reporting period. Several other hedge funds have also recently modified their holdings of the stock. Occudo Quantitative Strategies LP acquired a new stake in U.S. Gold in the fourth quarter valued at $73,000. JPMorgan Chase & Co. raised its stake in U.S. Gold by 93.8% in the 4th quarter. JPMorgan Chase & Co. now owns 14,117 shares of the technology company’s stock valued at $87,000 after purchasing an additional 6,831 shares during the last quarter. Walleye Capital LLC purchased a new stake in U.S. Gold in the 4th quarter valued at about $114,000. Cubist Systematic Strategies LLC